Mass General team presents mouse data to back the case for using reformulated asthma drug to treat ALS

Amber Tong

Can a reformulation of an old drug on the market for asthma, allergy and mastocytosis protect against liver disease, Alzheimer’s, and amyotrophic lateral sclerosis? …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Mass General team presents mouse data to back the case for using reformulated asthma drug to treat ALS

Amber Tong

Sign up to read this article for free.

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Novo Nordisk trims growth forecast as GLP-1 compounder ban yet to go live

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Mass Gen­er­al team presents mouse da­ta to back the case for us­ing re­for­mu­lat­ed asth­ma drug to treat ALS

Amber Tong

Sign up to read this article for free.

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

No­vo Nordisk trims growth fore­cast as GLP-1 com­pounder ban yet to go live

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Mass General team presents mouse data to back the case for using reformulated asthma drug to treat ALS

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Novo Nordisk trims growth forecast as GLP-1 compounder ban yet to go live

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges